Literature DB >> 8815119

Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia.

C E Bush1, R M Donovan, N Markowitz, D Baxa, P Kvale, L D Saravolatz.   

Abstract

We investigated gender as a factor in viral load measurements for human immunodeficiency virus-infected patients. Forty antiretroviral-therapy-naive, age- and CD4-matched women and men were tested for serum RNA and p24 antigen levels prior to antiretroviral therapy and at approximately 12 weeks after therapy. No gender differences were observed for these two markers of viral load.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8815119      PMCID： PMC228928          DOI： 10.1128/jcm.34.4.970-972.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  5 in total

1.  Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients.

Authors:  S Vella; M Giuliano; M Floridia; A Chiesi; C Tomino; A Seeber; S Barcherini; R Bucciardini; S Mariotti
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

2.  Survival differences in patients with AIDS.

Authors:  G H Friedland; B Saltzman; J Vileno; K Freeman; L K Schrager; R S Klein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

3.  The spectrum of HIV-1-related disease among outpatients in New York City.

Authors:  A E Greenberg; P A Thomas; S H Landesman; D Mildvan; M Seidlin; G H Friedland; R Holzman; B Starrett; J Braun; E L Bryan
Journal:  AIDS       Date:  1992-08       Impact factor: 4.177

4.  Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.

Authors:  J W Mellors; L A Kingsley; C R Rinaldo; J A Todd; B S Hoo; R P Kokka; P Gupta
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

5.  Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease.

Authors:  C Verhofstede; S Reniers; F Van Wanzeele; J Plum
Journal:  AIDS       Date:  1994-10       Impact factor: 4.177
  5 in total
  7 in total

1.  [Viral load--significance for individualized therapy].

Authors:  H Jäger
Journal:  Med Klin (Munich)       Date:  1997-06-15

2.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

Review 3.  Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective.

Authors:  Anna Thorner; Eric Rosenberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups.

Authors:  C M Lyles; D Vlahov; H Farzadegan; J Astemborski; J B Margolick; B A Masters; J Schroeder; T C Quinn
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

5.  Viral Load Monitoring in HIV Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

Review 6.  Sex Differences in HIV Infection.

Authors:  Eileen P Scully
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

7.  Sex Differences in HIV Infection: Mystique Versus Machismo.

Authors:  Eileen P Scully
Journal:  Pathog Immun       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.